Tripronucleated-ICSI human embryos (TPN) display different morphokinetic behaviour according to ploidy; TPN-ICSI that self-correct to diploidy are morphokinetically closer to correctly fertilized embryos. The morphokinetic variable t5 can predict ploidy.
Coenzyme Q (CoQ)-dependent mitochondrial activity in granulosa cells reduces with aging and is restored via supplementation, indicating that functional CoQ10 deficit is the main underlying cause for oxidative phosphorylation dysfunction.
Long-term intranasal oxytocin and placebo administration improve sexual function and symptoms of depression in women over time with no treatment, sequence (placebo first/second), or interaction effect.
Insulin resistance was found to be linked to depression risk, after controlling for potential confounders, in women who have polycystic ovary syndrome.
Vitamin D3 or its hypocalcemic analog, paricalcitol, may be a novel therapeutic approach as an effective, safe, nonsurgical treatment option for uterine fibroids.
Comprehensive preimplantation genetic screening and sperm DNA fragmentation analysis may play a role in predicting reproductive outcomes in IVF cycles for males carrying balanced chromosome reorganizations.
Cancer cells present in ovarian tissue may be found in isolated follicle suspensions. Manually washing the follicles three times proved effective for eliminating cancer cells while maintaining good follicle viability.
We conducted a meta-analysis and identified a significant but not strong association between thyroid antibodies and gestational diabetes mellitus, and that thyroid antibodies in the first trimester lack predictive value for gestational diabetes mellitus risk.
Dienogest promotes the induction of autophagy in endometriotic cells by suppressing protein kinase B and extracellular-signal-regulated kinase 1/2 activity, which results in mTOR inhibition, ultimately leading to increased apoptosis.
Introducing the slope of linear regression of b-human chorionic gonadotropin as an new independent risk factor for gestational trophoblastic neoplasia was demonstrated to be clinically justfiable and suitable to be considered in prevention programs.
Using a cut point of 0.5 ng/mL, antimullerian hormone (AMH) performs well to identify patients at risk of failure of ovarian stimulation for in vitro fertilization. PicoAMH does not provide superior ability to predict failed response.
Risk factors for suboptimal response to gonadotropin-releasing hormone agonist-agonist trigger include low luteinizing hormone (LH) and follicle stimulating hormone on in vitro fertilization cycle start day, low LH on trigger day, history of irregular menses, and long-term oral contraceptive use.
Antimullerian hormone (AMH) levels <1 ng/mL are associated with a statistically significantly lower likelihood of supernumerary good-quality blastocyst cryopreservation as compared with AMH levels between 1 and 4 ng/mL.
Monochorionic twins after assisted reproductive technology (ART) are at increased risk of adverse perinatal outcomes compared with spontaneous monochorionic twins and with dichorionc twins conceived by ART.
Endometrial pattern, but not thickness, on trigger day affected a patient’s chance of achieving a pregnancy. The pattern or thickness at embryo transfer had no effect.
Diminished ovarian reserve (DOR) assignment increased 7% among all Society for Assisted Reproductive Technology Clinic Outcomes Reporting System cycles from 2004 to 2011, despite minimal increase in patient age at cycle start. The ability of DOR assignment to predict poor ovarian response worsened.
Transfer of nonpronuclear (0PN) embryos results in pregnancies and live births. Blastocyst cultures can provide a better way to select normal 0PN embryos for transfer and thus achieve satisfactory outcomes.
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us
and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.